Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ovarian cancer chemoresistance poses a major challenge, driven by complex mechanisms. This review explores gene regulation by non-coding RNA and nuclear receptors in ovarian cancer chemoresistance.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Ovarian cancer (OC) is a leading cause of cancer mortality in women, with advanced stages presenting treatment challenges.
- Current standard treatment involves debulking surgery followed by platinum and taxane chemotherapy.
- Chemoresistance, both intrinsic and acquired, significantly limits treatment efficacy and leads to high relapse rates in OC patients.
Purpose Of The Study
- To review the multifactorial mechanisms of chemoresistance in ovarian cancer.
- To elucidate the roles of non-coding RNA (ncRNA) and nuclear receptors in regulating gene expression that confers chemoresistance.
- To provide a comprehensive understanding of the molecular drivers of chemoresistance in OC.
Main Methods
- Literature review of studies on ovarian cancer chemoresistance mechanisms.
- Analysis of genes involved in transport systems, apoptosis, DNA repair, and ovarian cancer stem cells (OCSCs).
- Examination of the regulatory roles of ncRNA and nuclear receptors in gene expression related to chemoresistance.
Main Results
- Chemoresistance involves complex mechanisms including altered transport, apoptosis evasion, enhanced DNA repair, and ovarian cancer stem cells (OCSCs).
- Genes associated with these mechanisms are critical, but their regulation by ncRNA and nuclear receptors is underexplored.
- ncRNA and nuclear receptors significantly modulate gene expression, influencing the development and progression of chemoresistance.
Conclusions
- Understanding the interplay between genes, ncRNA, and nuclear receptors is crucial for deciphering ovarian cancer chemoresistance.
- Targeting these regulatory pathways may offer novel therapeutic strategies to overcome chemoresistance.
- Further research into ncRNA and nuclear receptor functions is essential for improving OC patient outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...